Corcept Therapeutics (CORT) Gross Margin (2012 - 2026)

Corcept Therapeutics has disclosed Gross Margin across 15 years of filings, most recently posting 98.25% for Q1 2026.

• Gross Margin for Q1 2026 came in at 98.25%, down 22.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 98.25% (down 18.0% YoY), and the FY2025 annual result was 98.3%, down 9.0% from the prior year.
• Gross Margin came in at 98.25% for Q1 2026 at Corcept Therapeutics, roughly flat from 98.74% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 98.74% in Q4 2025 to a low of 97.79% in Q3 2025.
• The 5-year median for Gross Margin is 98.56% (2022), against an average of 98.49%.
• Peak annual rise in Gross Margin reached 37 bps in 2025, while the deepest fall reached 64 bps in 2025.
• Corcept Therapeutics' Gross Margin stood at 98.56% in 2022, then advanced by 0 bps to 98.61% in 2023, then retreated by 0 bps to 98.37% in 2024, then advanced by 0 bps to 98.74% in 2025, then decreased by 0 bps to 98.25% in 2026.
• The last three Gross Margin figures came in at 98.25% (Q1 2026), 98.74% (Q4 2025), and 97.79% (Q3 2025), per Business Quant data.